Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11327841 | 0.85 | HPGD (0.58) | HPGDPKMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7358239 | 0.84 | HPGD (0.51) | HPGDPKMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL411064 | 0.82 | PKM (0.50) | HPGDPKMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7355574 | 0.82 | HPGD (0.46) | HPGDPKMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7828291 | 0.81 | ANPEP (0.43) | HPGDALDH1A1ANPEPDPP4KMT2A | |
| SCHEMBL3790518 | 0.79 | KMT2A (0.52) | HPGDPKMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12638925 | 0.77 | KMT2A (0.61) | HPGDPKMALDH1A1MAPTKMT2A | |
| SCHEMBL31540930 | 0.76 | ANPEP (0.55) | HPGDALDH1A1MAPTSMN1; SMN2ANPEP | |
| SCHEMBL6503782 | 0.76 | KMT2A (0.56) | HPGDALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL12235610 | 0.76 | ANPEP (0.58) | HPGDALDH1A1MAPTSMN1; SMN2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435048-B1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2435048-B1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-03 | — | — | EP | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2632461-A1 | ISOINDOLINONE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| WO-2012058133-A1 | ISOINDOLINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058133-A1 | ISOINDOLINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | PDE5A, PDE3A, PDE10A | HPGD 194/4885PKM 648/4885ALDH1A1 301/4885 |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | PDE12, PDE10A, PDE4A | HPGD 172/4885PKM 1760/4885ALDH1A1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.